If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
90.00    0.00 (0.00%)
Bid:
85.00
Ask:
95.00
Spread: 10.00 (11.765%)
Market Cap: £5.92m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Long Term Contract with NCHCD

12 Oct 2016 07:00

RNS Number : 2818M
Crimson Tide PLC
12 October 2016
 

Crimson Tide PLC

("Crimson Tide" or the 'Company')

Crimson Tide signs long term contract with National Centre for Hereditary Coagulation Disorders (NCHCD)

 

Crimson Tide ﴾TIDE﴿, the AIM‐quoted provider of mpro5 ‐ Smart Mobility as a Service, has entered into a contract with the NCHCD in Ireland, whereby mpro5 will deliver its healthcare solution to patients in the management of treatment for hereditary coagulation disorders, commonly known as haemophilia.

 

The contract value is worth approximately €140,000 in revenue over a term of 36 months, which includes delivery of the mpro5 mobility solution directly to patients. This is the first contract Crimson Tide has signed directly with the NCHCD as previously its solutions were delivered via a third party.

 

Patients at home use mpro5 to scan medication they receive from the hospital. The barcode information is then sent to a central hub for verification of type and date ranges. Confirmation is then returned to the patient, informing them of the medication validity and safe administration.

 

New functionality now improves this process, - including verification of stock levels and expiry date prompts, thereby providing further information to the patient and assisting in reducing stock wastage.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "We are delighted to be able to work directly with the NCHCD in providing patients with hereditary coagulation disorders a solution to manage their use of prescribed pharmaceutical products. This empowers patients to manage their condition and provides the NCHCD with valuable real time information."

 

For further information:

Crimson Tide plc

 

Barrie Whipp/Steve Goodwin 01892 542 444

 

WH Ireland

James Joyce /James Bavister 020 7220 1666

 

Notes to editors

1. Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 ‐ Smart Mobility as a Service (SMaaS). mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

2. Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world‐class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

3. mpro5 is a platform‐agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

4. mpro5 not only helps people improve their day‐to‐day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to listen, share and find the best solution for all mobility needs.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKFLFFQBFEFBD
Date   Source Headline
2nd Mar 20107:00 amRNSChange of Adviser
20th Oct 20097:00 amRNSChange of Adviser
1st Oct 20099:39 amRNSTotal Voting Rights
8th Sep 20097:00 amRNSDisposal of part of trade in Ireland
2nd Sep 20097:01 amRNSBlocklisting Interim Review
2nd Sep 20097:00 amRNSExercise of Warrants and Director Dealing
11th Aug 20095:45 pmRNSHalf Yearly Report (Replacement)
11th Aug 20097:00 amRNSHalf Yearly Report
30th Jun 20091:00 pmRNSResult of AGM
16th Jun 20097:00 amRNSAcquisition of Trade
9th Jun 200910:10 amRNSAnnual Financial Report
8th Jun 20097:00 amRNSFinal Results
29th May 20093:53 pmRNSHolding(s) in Company
28th May 20097:00 amRNSYes Telecom Partnership
1st May 20091:13 pmRNSTotal Voting Rights
1st May 20091:11 pmRNSBlocklisting Interim Review
20th Jan 20092:49 pmRNSDirector/PDMR Shareholding
6th Nov 200811:47 amRNSGrant of Options
31st Oct 20087:00 amRNSBlocklisting Interim Review
25th Sep 20082:20 pmRNSInterim Results - Correction
25th Sep 20087:00 amRNSInterim Results
6th Aug 20087:00 amRNSBorrowing Facility
25th Jul 200812:20 pmRNSResult of AGM
21st Jul 20087:00 amRNSDirector/PDMR Shareholding
30th Jun 20088:51 amRNSAnnual Report and Accounts
30th Jun 20087:00 amRNSPreliminary Results
30th May 20084:30 pmRNSTotal Voting Rights
1st May 200810:44 amRNSIssue of Equity
1st May 200810:37 amRNSBlocklisting Interim Review
30th Apr 20084:30 pmRNSTotal Voting Rights
25th Apr 200812:23 pmRNSResult of General Meeting
24th Apr 20087:01 amRNSEntered for Microsoft Award
23rd Apr 20083:58 pmRNSPlacing & Borrowing Facility
10th Apr 20084:22 pmRNSNotice of General Meeting
4th Apr 20085:41 pmRNSDirector/PDMR Shareholding
18th Feb 20087:00 amRNSContract Win - Heatons & DL&T
28th Jan 20087:01 amRNSContract Win - Ski Club
10th Dec 20077:01 amRNSContract Win - Knight Frank
31st Oct 20074:31 pmRNSTotal Voting Rights
31st Oct 20074:30 pmRNSBlocklisting Interim Review
27th Sep 20078:00 amRNSInterim Results
24th Aug 20072:28 pmRNSHolding(s) in Company
16th Aug 20073:14 pmRNSHolding(s) in Company
13th Aug 20075:38 pmRNSAim Rule 26 Information
19th Jul 20077:01 amRNSMicrosoft Partner Conference
29th Jun 20074:30 pmRNSTotal Voting Rights
18th Jun 20077:01 amRNSNew business partnership
5th Jun 20073:59 pmRNSShare Placing
5th Jun 20072:06 pmRNSGranting of share options
5th Jun 200711:27 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.